GlassScriptPhysician profile
Sylvain S Silberstein
NPI 1710038427
$3,813.00
in general payments reported to CMS, 2019-2025
40 companies · $298 in 2025
The $298 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $350 · 2020: $462 · 2021: $701 · 2022: $1,100 · 2023: $482 · 2024: $421 · 2025: $298.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,177 · Education: $24.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,176.90 |
| Education | $24.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $830.28 | 2020-2024 | Ozempic, Rybelsus, Saxenda |
| Dexcom, INC. | $434.24 | 2021-2024 | Dexcom G6 Transmitter |
| Insulet Corporation | $254.92 | 2019-2023 | Omnipod |
| Boehringer Ingelheim Pharmaceuticals, INC. | $214.72 | 2020-2025 | Jardiance |
| Abbvie INC. | $203.14 | 2021-2025 | Qulipta |
| Lilly USA, LLC | $182.26 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Amgen INC. | $160.08 | 2019-2025 | Evenity, Prolia, Tepezza |
| Mannkind Corporation | $144.28 | 2019-2020 | |
| Abbott Laboratories | $130.99 | 2021-2022 | |
| Tandem Diabetes Care, INC. | $91.96 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $83.77 | 2020-2024 | Breztri |
| Vistapharm, INC. | $80.35 | 2021 | |
| Medtronic, INC. | $78.17 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $69.05 | 2019-2021 | |
| Companion Medical, INC. | $65.58 | 2019-2020 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sylvain Silberstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.